SCA
RVNC

SAC Capital Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

SAC Capital Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-8,395
Closed -$264K – 1093
2014
Q1 		$264K Buy
+8,395
New +$262K ﹤0.01% 1455

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

SAC Capital Advisors's RVNC Position: Q2 2014 in Review

SAC Capital Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2014, closing a stake of 8,395 shares — an estimated $264K sold.

SAC Capital Advisors first reported a position in RVNC in Q1 2014 and held it in 1 quarter. The position peaked at $264K in Q1 2014. 98 funds tracked by Wall St. Rank hold RVNC as of Q2 2014.

  • SAC Capital Advisors reported no remaining Revance Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 8,395 Revance Therapeutics, Inc. shares in Q2 2014, an estimated $264K.
  • SAC Capital Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Revance Therapeutics, Inc. position peaked at $264K in Q1 2014.
  • 98 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.